Expanded Access to ABBV-CLS-484
NCT06188975 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-01-03
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
- Advanced Solid Tumor Cancer
Interventions
- DRUG
-
DRUG: ABBV-CLS-484
Sponsors & Collaborators
-
Calico Life Sciences LLC
lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
NCT04417465 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
NCT05162443 ·Status: APPROVED_FOR_MARKETING
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03821935 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
NCT02955251 ·Status: COMPLETED ·Phase: PHASE1
-
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
NCT01110486 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
NCT03234712 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
NCT01648764 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365662 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
NCT02988960 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
NCT01478685 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Advanced Cancer
NCT01226485 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
NCT04673942 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of ABT-414 in Subjects With Solid Tumors
NCT01741727 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Advanced Solid Tumor Patients
NCT07300943 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
NCT04272203 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
NCT03000257 ·Status: COMPLETED ·Phase: PHASE1
-
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
NCT01317420 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of LY2584702 in Participants With Advanced Cancer
NCT01394003 ·Status: TERMINATED ·Phase: PHASE1
-
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
NCT04504513 ·Status: APPROVED_FOR_MARKETING